Table 1.
List of drugs under clinical trials for targeting neutrophils in various chronic inflammatory diseases
| Drug | Mode of action | Diseases | Clinical trial phase | Clinical Trials.gov identifier |
|---|---|---|---|---|
| BAY85-8501 | Human neutrophil elastase (NE) inhibitor | Non-CF bronchiectasis | Phase 2 | NCT01818544 |
| POL6014 | Cystic fibrosis | Phase 1 | NCT03748199 | |
| CHF 6333 | Cystic fibrosis | Phase 1 | NCT04010799 | |
| Elafin | Pulmonary arterial hypertension | Phase 1 | NCT03522935 | |
| Crisaborole ointment 2% | Phosphodiesterase 4 (PDE4) inhibitor | Atopic dermatitis | Phase 4 | NCT03356977 |
| Ensifentrine | COPD | Phase 3 | NCT04535986 | |
| Roflumilast | COPD | Phase 4 | NCT01329029 | |
| Apremilast | Psoriatic arthritis | Phase 4 | NCT02425826 | |
| Disulfiram | GSDMD (NETs) | COVID-19 | Phase 2 | NCT04594343 |
| Pulmozyme | DNase I (NETs) | COVID-19 | Phase 2 | NCT04402944 |
| AZD5069 | CXCR2 antagonist | Bronchiectasis | Phase 2 | NCT01255592 |
| Canakinumab | IL-1b (mAb) | COVID-19-pneumonia | Phase 3 | NCT04362813 |
| Tocilizumab | IL-6 (mAb) | COVID-19-pneumonia | Phase 2 | NCT04317092 |
| Brensocatib | Dipeptidyl peptidase 1 (DPP-1) Inhibitor | Non-cystic fibrosis bronchiectasis | Phase 3 | NCT04594369 |
| N-acetylcysteine | Respiratory burst | COVID-19 | Phase 2 | NCT04419025 |
| Ixekizumab | IL-17A (mAb) | Psoriatic, arthritis | Phase 3 | NCT01695239 |
| Risankizumab | IL-23 (mAb) | Psoriasis | Phase 3 | NCT02684370 |
| Colchicine | Microtubule polymerization inhibitor | COVID-19 | Phase 3 | NCT04322682 |